e-learning
resources
Conferences
ERS Satellites
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Talk from Warsaw – Tailoring drug therapy in idiopathic pulmonary fibrosis
Wim Wuyts (BL)
Source:
ERS Satellites 2019
Number:
9
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Wim Wuyts (BL). Talk from Warsaw – Tailoring drug therapy in idiopathic pulmonary fibrosis. ERS Satellites 2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard
Source: Eur Respir J 2015; 45: 1208-1210
Year: 2015
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Impact of an interstitial lung diseases Nurse on the compliance to anti-fibrotic drugs in patients with Idiopathic Pulmonary Fibrosis.
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD
Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions
Year: 2013
Pulmonary rehabilitation in idiopathic pulmonary fibrosis: Predictors of adherence and exercise improvement
Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation
Year: 2013
Triple therapy in idiopathic pulmonary fibrosis: an alarming press release
Source: Eur Respir J 2012; 39: 805-806
Year: 2012
Antifibrotic choice in idiopathic pulmonary fibrosis
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
The therapy of idiopathic pulmonary fibrosis: what is next?
Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019
Year: 2019
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
ERJ
March Podcast: Novel therapies in idiopathic pulmonary fibrosis
Source: Eur Respir J, 53 (3) 19E5303; 10.1183/13993003.E5303-2019
Year: 2019
IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1434-1445
Year: 2015
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
Source: Eur Respir Rev, 29 (157) 190158; 10.1183/16000617.0158-2019
Year: 2020
Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021
Year: 2021
Benefits of pulmonary rehabilitation and predictor of changes in exercise capacity for idiopathic pulmonary fibrosis
Source: International Congress 2014 – Latest insights in pulmonary rehabilitation
Year: 2014
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept